Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 3, 2004, Pages 185-193

  Barden, Nicholas ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antidepressive agents; Corticotropin; Depression; Hypothalamus; Models, animal; Pituitary adrenal system; Receptors, glucocorticoid

Indexed keywords

ANTIDEPRESSANT AGENT; COMPLEMENTARY RNA; CORTICOSTERONE; CORTICOTROPIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; REBOXETINE;

ADRENAL GLAND; CONFERENCE PAPER; CORTICOTROPIN RELEASE; CUSHING SYNDROME; DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; GENETIC COMPLEMENTATION; GENETIC TRANSCRIPTION; HORMONE BINDING; HYDROCORTISONE RELEASE; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOOD DISORDER; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SEROTONIN RELEASE; TISSUE SPECIFICITY; TRANSGENIC MOUSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; MUTATION, MISSENSE; PITUITARY-ADRENAL SYSTEM; RNA, ANTISENSE;

EID: 3042662118     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Jasper MS, Engeland WC. Splanchnic neural activity modulates ultradian and circadian rhythms in adrenocortical secretion in awake rats. Neuroendocrinology 1994;59:97-109.
2. Cascio CS, Shinsako J, Dallman MF. The suprachiasmatic nuclei stimulate evening ACTH secretion in the rat. Brain Res 1987;423:173-9.
3. Szafarczyk A, Alonso G, Ixart G, Malaval F, Assenmacher I. Diurnal-stimulated and stress-induced ACTH release in rats is mediated by ventral noradrenergic bundle. Am J Physiol 1985;249:E219-26.
4. Beaulieu S, Pelletier G, Vaudry H, Barden N. Influence of the central nucleus of the amygdala on the content of corticotropin-releasing factor in the median eminence. Neuroendocrinology 1989;49:255-61.
5. Beaulieu S, De Paolo T, Côté J, Barden N. Participation of the central amygdaloid nucleus in the response of adrenocorticotropin secretion to immobilization stress: opposing roles of the noradrenergic and dopaminergic systems. Neuroendocrinology 1987;45:37-46.
6. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991;12:118-34.
7. Reul JMHM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505-12.
8. Cintra A, Zoli M, Rosen L, Agnati LF, Okret S, Wikstrom AC, et al. Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. Neuroscience 1994;62:843-97.
9. de Kloet ER. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991;12:95-164.
10. Funder JW. Corticosteroid receptors and the central nervous system. J Steroid Biochem Mol Biol 1994;49:381-4.
11. Ratka A, Sutanto W, Bloemers M, de Kloet ER. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 1989;50:117-23.
12. Bradbury MJ, Akana SF, Cascio CS, Levin N, Jacobson L, Dallman MF. Regulation of basal ACTH secretion by corticosterone is mediated by both type I (MR) and type II (GR) receptors in rat brain. J Steroid Biochem Mol Biol 1991;40:133-42.
13. Dallman MF, Levin N, Cascio CS, Akana SF, Jacobson L, Kuhn RW. Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology 1989;124:2844-50.
14. Regestein QR, Rose LI, Williams GH. Psychopathology in Cushing's syndrome. Arch Intern Med 1972;130:114-7.
15. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 1976;33:1039-50.
16. Von Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone-human corticotropin-releasing-hormone challenge in patients with depression. J Neuroendocrinol 1989;1:485-8.
17. Murphy BE. Steroids and depression. J Steroid Biochem Mol Biol 1991;38:537-59.
18. Linkowski P, Kerkhofs M, Van Onderbergen A, Hubain P, Copinschi G, l'Hermite-Baleriaux M, et al. The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry 1994;51:616-24.
19. Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Müller OA. Blunted corticotropin and normal cortisol response to human corticotropin- releasing factor (h-CRF) in depression. N Engl J Med 1984;311:1127.
20. Holsboer F, Gerken A, Stalla GK, Müller OA. ACTH, cortisol and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery. Biol Psychiatry 1985;20:276-86.
21. Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Müller OA, et al. Human corticotropin-releasing hormone in depression. Biol Psychiatry 1986;21:601-11.
22. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, et al. Psychiatric implications of basic and clinical studies with corticotropin- releasing factor. Am J Pyschiatry 1984;141:619-27.
23. Holsboer F, Spengler D, Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. In: Swaab DF, Hofman MA, Mirmiran M, Ravid R, van Leeuwen FW, editors. Progress in brain research. Vol. 93. Amsterdam: Elsevier; 1992. p. 385-417.
24. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71-100.
25. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991;43:425-73.
26. Nemeroff CB, Widerlov E, Bisette G, Walléus H, Karlson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-3.
27. Raadsheer FC, Hoogendijk WJG, Stam FQ Tilders FJH, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436-44.
28. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988; 45:577-9.
29. Gold PW, Loriaux DL, Roy A. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314:1329-35.
30. Von Bardeleben U, Stalla GK, Müller OA, Holsboer F. Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pre-treatment. Biol Psychiatry 1988; 24:782-6.
31. Lisansky J, Peake GT, Strassman RJ, Qualls C, Meikle AW, Risch C, et al. Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pre-treated with metyrapone. Arch Gen Psychiatry 1989;46:641-9.
32. Gershon ES, Targum SD, Kessler LR, Mazure CM, Bunney WE Jr. Genetic studies and biologic strategies in the affective disorders. Prog Med Genet 1977;2:101-64.
33. Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic-depressive disorders. Br J Psychiatry 1977;130:330-51.
34. Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991;38:163-71.
35. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 1991;48:693-9.
36. Gotthardt U, Schweiger U, Fahrenberg J, Lauer C, Holsboer F, Heuser I. Cortisol, ACTH and cardiovascular resposes to a cognitive challenge paradigm in aging and depression. Am J Physiol 1995;268:R865-73.
37. Heuser I, Gotthardt U, Schweiger, U, Schmider J, Lammers CH, Dettling M, et al. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging 1994;15:227-31.
38. Sapolsky RM, Krey LC, McEwen BS. Glucocorticoid-sensitive hippocampal neurons are involved in terminating the adrenocortical stress response. Proc Natl Acad Sci USA 1984;81:6174-7.
39. Brooke SM, Haasjohnson AM, Kaplan JR, Manuck SB, Sapolsky RM. Dexamethasone resistance among nonhuman primates associated with a selective decrease of glucocorticoid receptors in the hippocampus and a history of social instability. Neuroendocrinology 1994;60:134-40.
40. Peiffer A, Barden N, Meaney MJ. Age-related changes in glucocorticoid receptor binding and mRNA levels in the rat brain and pituitary. Neurobiol Aging 1991;12:475-9.
41. Sapolsky RM, Krey LC, McEwen BS. The adrenocortical stress-response in the aged male rat: impairment of recovery from stress. Exp Gerontol 1983;18:55-64.
42. Halbreich U, Asnis GM, Zumoff B, Nathan RS, Shindledecker R. Effect of age and sex on cortisol secretion in depressives and normals. Psychiatry Res 1984;13:221-9.
43. Whalley LJ, Borthwick N, Copolov D, Dick H, Christie JE, Fink G. Glucocorticoid receptors and depression. BMJ 1986;292:859-61.
44. Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid receptor function in transgenic mice expressing antisense RNA. Nature 1992;355:725-8.
45. Stec I, Barden N, Reul JMHM, Holsboer F. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J Psychiatr Res 1994;28:1-5.
46. Barden N, Stec ISM, Montkowski A, Holsboer F, Reul JMHM. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 1997;66:212-20.
47. Barden N. Corticosteroid receptor modulation in transgenic animals. Ann N Y Acad Sci 1994;746:89-100.
48. Richard D, Chapdelaine S, Deshaies Y, Pepin MC, Barden N. Energy balance and lipid metabolism in transgenic mice bearing an antisense glucocorticoid receptor gene construct. Am J Physiol 1993;265:146-50.
49. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, et al. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 1995;7:841-5.
50. Rousse I, Beaulieu S, Rowe W, Meaney MJ, Barden N, Rochford J. Spatial memory in transgenic mice with impaired glucocorticoid receptor function. NeuroReport 1997;8:841-5.
51. Rochford J, Beaulieu S, Rousse I, Glowa JR, Barden N. Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: effects of diazepam and FG-7142. Psychopharmacology 1997;132:145-52.
52. Rousse I, Beaulieu S, Barden N, Rochford J. Spatial memory in transgenic mice with impaired glucocorticoid receptor function. Neuroreport 1997;8:841-5.
53. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 1999; 23:99-103.
54. Young EA, Haskett RF, Grunhaus L, Pande A, Weinberg VM, Watson SJ, et al. Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Arch Gen Psychiatry 1994;51:701-7.
55. Vamvakopoulos NC, Chrousos GP. Structural organization of the 5′ flanking region of the human corticotropin releasing hormone gene. DNA Seq 1993;4:197-206.
56. Barden N, Reul JMHM, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1995;18:6-11.
57. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 1996;17:187-205.
58. Ban TA. Psychopharmacology of depression. New York: Karger; 1981.
59. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. Dexamethasone suppression test in antidepressant treatment of melancholia: the process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983;40:493-500.
60. Hoslboer F, Liebl R, Hifschuster E. Repeated dexamethasone suppression test during depressive illness. Nomalization of test result compared with clinical improvement. J Affect Disord 1982;4:93-101.
61. Beaulieu S, Barden N. Antidepressant, serotoninergic and glucocorticoid modulation of glucocorticoid receptor messenger RNA in hypothalamic neurons. Neuroendocrinol Lett 1987;9:186.
62. Pepin MC, Beaulieu S, Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol Brain Res 1989;6:77-83.
63. Reul JMHM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993;133:312-20.
64. Reul JMHM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994; 60:509-19.
65. Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, Ogren SO, et al. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. J Neural Transm 1988;73:191-203.
66. Hanin I, Frazer A, Croughan J, Davis JM, Katz MM, Koslow SH, et al. Depression: implications of clinical studies for basic research. Fed Proc 1985;44:85-90.
67. Pepin MC, Govindan MV, Barden N. Increased glucocorticoid receptor gene promoter activity following antidepressant treatment. Mol Pharmacol 1992;41:1016-22.
68. Pepin MC, Barden N. Decreased glucocorticoid receptor activity following glucocorticoid receptor anti-sense RNA gene fragment transfection. Mol Cell Biol 1991;11:1647-53.
69. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87:831-7.
70. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996;29:12-22.
71. Peiffer A, Veilleux S, Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor mRNA levels in rat brain. Psychoneuroendocrinology 1991;16:505-15.
72. Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55:621-6.
73. Kvetnansky R, Fukuhara K, Pacak K, Cizza G, Goldstein DS, Kopin IJ. Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology 1993;133:1411-9.
74. Murphy BEP, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18:209-13.
75. Spurlock G, Buckland P, O'Donovan M, McGuffin P. Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology 1994;33:433-40.
76. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density and mRNA level. J Neurosci 1999;19:10494-501.
77. Beaulieu S, Di Paolo T, Côte. J, Barden N. Participation of the central amygdaloid nuleus in the response of adrenocorticotropin secretion to immobilization stress: opposing roles of the noradrenergic and dopaminergic systems. Neuroendocrinology 1987;45:37-46.
78. Singh VB, Corley KC, Phan T, Boadle-Biber MC. Increases in the activity of tryptophan hydroxylase from rat cortex and midbrain in response to acute or repeated sound stress are blocked by adrenalectomy and restored by dexamethasone treatment. Brain Res 1990;516:66-76.
79. Kuroda Y, Mikuni M, Ogawa T, Takahashi K. Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors. Psychopharmacology 1992;108:27-32.
80. Mendelson SD, McEwen BS. Autoradiographic analyses of the effects of restraint-induced stress on 5-HT1A, 5-HT1C and 5-HT2 receptors in the dorsal hippocampus of male and female rats. Neuroendocrinology 1991;54:454-61.
81. Biegon A, Rainbow TC, McEwen B. Corticosterone modulation of neurotransmitter receptors in rat hippocampus: a quantitative autoradiographic study. Brain Res 1985;332:309-14.
82. Young AH, MacDonald LM, St John H, Dick H, Goodwin GM. The effects of corticosterone on 5-HT receptor function in rodents. Neuropharmacology 1992;31:433-8.
83. Chalmers DT, Lopez JF, Vazquez DM, Akil H, Watson SJ. Regulation of hippocampal 5-HT1A receptor gene expression by dexamethasone. Neuropsychopharmacology 1994;10:215-22.
84. Maes M, Meltzer HYM. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1994. p. 933-44.
85. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion - enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994;51:687-97.
86. Maes M, Meltzer HY, D'Hondt P, Cosyns P, Blockx P. Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. Psychoneuroendocrinology 1995;20:149-67.
87. de Kloet ER, Kovacs GL, Szabo G, Telegdy G, Bohus B, Versteeg DHG. Decreased serotonin turnover shortly after adrenalectomy: selective normalization after corticosterone substitution. Brain Res 1982;239:659-63.
88. Seckl JR, Dickson KL, Fink G. Central 5,7-dihydroxytryptamine lesions decrease hippocampal glucocorticoid and mineralocorticoid receptor messenger ribonucleic acid expression. J Neuroendocrinol 1990;2:911-6.
89. Ogawa T, Mikuni M, Kuroda Y, Muneoka K, Mori KJ, Takahashi K. Effects of the altered serotonergic signalling by neonatal treatment with 5,7-dihydroxytryptamine, ritanserin or clomipramine on the adrenocortical stress response and the glucocorticoid receptor binding in the hippocampus in adult rats. J Neural Transm Gen Sect 1994;96:113-23.
90. Silva CM, Powell-Oliver FE, Jewell CM, Sar M, Allgood VE, Cidlowski JA. Regulation of the human glucocorticoid receptor by long-term and chronic treatment with glucocorticoid. Steroids 1994;59:436-42.
91. Yau JLW, Seckl JR. Central 6-hydroxydopamine lesions decrease mineralocorticoid, but not glucocorticoid receptor gene expression in the rat hippocampus. Neurosci Lett 1992;142:159-62.
92. Laakmann G, Hennig J, Baghai T, Schule C. Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology 2003;47:31-6.
93. Szabo ST, Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001;25:845-57.
94. Yau JL, Kelly PA, Seckl JR. Increased glucocorticoid receptor gene expression in the rat hippocampus following combined serotonergic and medial septal cholinergic lesions. Mol Brain Res 1994;27:174-8.